Evidence map›Paper›PMID 33079318›Full record

ReviewPituitary2021

A Pituitary Society update to acromegaly management guidelines.

Maria Fleseriu, Beverly M K Biller, Pamela U Freda, Monica R Gadelha, Andrea Giustina, Laurence Katznelson, Mark E Molitch, Susan L Samson, Christian J Strasburger, A J van der Lely and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pituitary, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 165 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
165citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

165 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Clinical characteristics associated with somaticFrontiers in endocrinology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Uterine fibroids in women diagnosed with acromegaly: a systematic review.Reviews in endocrine & metabolic disorders · 2024
    Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Review
  20. Article

105 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maria FleseriuPituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0001-9284-6289
Beverly M K BillerNeuroendocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Pamela U FredaDepartment of Medicine, Columbia University, Vagelos College of Physicians and Surgeons, New York, NY, USA.
Monica R GadelhaNeuroendocrinology Research Center/Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.
Andrea GiustinaInstitute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS San Raffaele Hospital, Milan, Italy.
Laurence KatznelsonDepartments of Medicine and Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Mark E MolitchDivision of Endocrinology, Metabolism & Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Susan L SamsonPituitary Center, Departments of Medicine and Neurosurgery, Baylor College of Medicine, Houson, TX, USA.
Christian J StrasburgerDepartment of Medicine for Endocrinology, Diabetes and Nutritional Medicine, Charité Universitätsmedizin, Berlin, Germany.
A J van der LelyPituitary Center Rotterdam, Endocrinology Section, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
Shlomo MelmedPituitary Center, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Room 2015, Los Angeles, CA, 90048, USA. melmed@csmc.edu.ORCID http://orcid.org/0000-0002-2355-3447

Funding

New Approaches to the Evaluation and Treatment of AcromegalyR01DK110771 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FREDA, PAMELA U · 2017 to 2020
$2.3M
NIDDK NIH HHS R01 DK110771
6 · The paper itself

Abstract

Guidelines and consensus statements ensure that physicians managing acromegaly patients have access to current information on evidence-based treatments to optimize outcomes. Given significant novel recent advances in understanding acromegaly natural history and individualized therapies, the Pituitary Society invited acromegaly experts to critically review the current literature in the context of Endocrine Society guidelines and Acromegaly Consensus Group statements. This update focuses on how recent key advances affect treatment decision-making and outcomes, and also highlights the likely role of recently FDA-approved therapies as well as novel combination therapies within the treatment armamentarium.

Indexed as

AcromegalyAnimalsFemaleHuman Growth HormoneHumansInsulin-Like Growth Factor IMaleOctreotidePituitary NeoplasmsReceptors, SomatostatinHuman Growth HormoneInsulin-Like Growth Factor IOctreotidepegvisomantReceptors, SomatostatinAcromegalyGrowth hormoneInsulin-like growth factor IOral octreotidePegvisomantPituitary adenomaSomatostatin receptor ligand

Identifiers

PMID33079318
PMCPMC7864830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.